Tuesday, November 30, 2021

波士頓市長假日列車12/5 下午2點開進華埠


Boston’s Enchanted Trolley Tour continues the festive tradition of lighting holiday trees throughout Boston’s neighborhoods


BOSTON - Thursday, December 2, 2021 - Mayor Michelle Wu today announced the schedule for this year's Enchanted Trolley Tour, a Boston holiday tradition of lighting holiday trees throughout the City. This year, the Mayor’s Enchanted Trolley Tour will take place on Friday, December 3, Saturday, December 4, and Sunday, December 5, in neighborhoods throughout Boston. This event is presented by Bank of America and includes visits with Santa, tree lightings, and more.

“It’s a joy to participate in our annual holiday trolley tour and tree lightings across the City,” said Mayor Michelle Wu. “The holiday season is a time for friends, family, and neighbors to come together and celebrate, and I am delighted to welcome all to attend this weekend of fun for families and residents.”

The 2021 Mayor’s Enchanted Trolley Tour and Tree Lightings Schedule is as follows: 

Friday, December 3, 2021

·    5:30 p.m. - Mattapan Square, Mattapan

·    6:15 p.m. - Wolcott Square, Readville

·    7 p.m. - Hastings Street Lot, Centre Street, West Roxbury

Saturday, December 4, 2021

·    1 p.m. - Codman Square, Dorchester

·    1:45 p.m. - Hyde Square, Jamaica Plain

·    2:30 p.m - J.P. Monument, Jamaica Plain

·    3:30 p.m. - Brigham Circle, Mission Hill

·    4:15 p.m. - Bolling Building, Roxbury

·    5:30 p.m. - Blackstone Square, South End

·    6:45 p.m. - Oak Square, Brighton

Sunday, December 5, 2021

·    1 p.m. - M Street Park, South Boston

·    2 p.m. - Beach Street & Harrison Avenue, Chinatown

·    3 p.m. - Paul Revere Mall, North End

·    4 p.m. - Thompson Square, Charlestown

·    5 p.m. - Maverick Square, East Boston

·    7 p.m. - Adams Corner, Dorchester

Follow the Mayor’s Office of Tourism, Sports, and Entertainment on social media @VisitBostonCity and visit boston.gov/visiting-boston to learn about more free, family-friendly events happening in the City of Boston.

This is an entirely outdoor, open-air event. It is encouraged, but not required, to wear masks. Individuals who are not fully vaccinated are still at high-risk of spreading COVID-19. If you are not fully vaccinated, you should avoid large social gatherings. If you do plan to attend, avoid congested areas, wear a mask to cover your nose and mouth, and maintain six feet of physical distance as much as possible. To get vaccinated, find a location near you on boston.gov/coronavirus.

2021 CABA Annual Conference 12/4

2021 CABA Annual Conference

2021 CABA Annual Conference

New Era, New Horizon - Explore with Industry Pioneers and Leaders on the New Frontiers in Healthcare Innovation

Date: Dec 4, 2021

Time: 8:45 am - 12:15 pm EST

Agenda and Speaker Profile

This year’s annual conference of CABA will host a collection of industry pioneers and leaders from a diverse background in science and business. These speakers will share exciting stories and developments and offer their insights in fields that will continue to improve human health, including RNA therapeutics, cell therapies, gene editing, and new materials and methods in life sciences. We hope you will join us and explore the new frontiers in healthcare innovation.



Bo Ying, PhD

Founder and CEO, Abogen Biosciences

CABA President (2018-2019)

Bo Ying, Ph.D., is the founder and CEO of Suzhou Abogen Biosciences, dedicated to mRNA-based therapeutics with focus on immune-oncology as well as infectious diseases. Dr. Ying has decades of experiences in drug development, and he is also an expert in drug delivery system such as lipid nanoparticles. He has successfully led team in the process of drug product development, CMC, tech transfer and IND application for a variety of nucleic acid-based therapeutics. As with the ongoing Covid-19 pandemic, Abogen has developed an mRNA-based vaccine and received IND approval from National Center for Drug Evaluation in China. Currently the vaccine product is under phase III clinical trial. Prior to founding Abogen, Dr. Ying has worked as group leader with proven track record of success at different biotech companies in Boston such as Dicerna Pharmaceuticals, Moderna

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.



Ke Xu, PhD

Founder, Chairman and CEO of VesiCURE

Extracellular Vesicles (EVs) for Drug Development and Delivery

Dr. Ke Xu is the founding CEO of VesiCURE Therapeutics. Dr. Xu received his Ph.D. in Genetics and Development from the University of Texas Southwestern Medical Center at Dallas. After that, he moved to Harvard University for his postdoc training with Drs. Andy McMahon and Doug Melton. In 2014, Dr. Xu joined Biogen to help set up neurodegenerative models using human iPSC and genome editing technologies. From 2016 and before VesiCURE, he worked at Codiak BioSciences, the first exosome therapeutic company in North America, focusing on discovery research and pipeline development.



Shi-Jiang (John) Lu, PhD, MPH

President and CEO of HebeCell Corporation

CAR NK Cells from 3D-iPSC Bioreactor: One Platform Endless Pipelines

Shi-Jiang (John) Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. Dr. Lu is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational researches and discovery of novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. Dr. Lu is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, his patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 year experiences in cancer research. Dr. Lu received his BS degree in Biochemistry from Wuhan University, MSc degree in Oncology/Pathophysiology from Peking Union Medical College, MPH degree in Molecular Toxicology/Environmental Sciences from Columbia University and PhD degree in Molecular Cancer Biology from the University of Toronto.

Therapeutics and Trucode Gene Repair. Dr. Ying received his bachelor and master’s degrees from Fudan University and a Ph.D. degree from Northeastern University in Boston, USA.



Ed Zhang, MBA

Co-founder and Interim CEO of Overland Pharmaceuticals, Venture Partner of Hillhouse Capital

Opportunities and Challenges for a Cross-border Cell Therapy NewCo.

Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and is Venture Partner at Hillhouse Capital. Prior to Overland, Mr. Zhang was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Mr. Zhang led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Before joining Boston Pharma, Mr. Zhang headed Global Business Development for Sanofi’s Renal Strategic Unit, and was Director of Commercial Operations and Strategic Development at Genzyme before its acquisition by Sanofi. Mr. Zhang started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 18 years of biopharma industrial experience to Overland. Mr. Zhang holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.



Eric von Hofe, PhD

President and COO of AffyImmune Therapeutics

Affinity Tune and Track CAR T Cell Technology for Solid Tumors

Eric von Hofe, Ph.D., has over 25 years of experience in biotechnology with a focus on cancer immunotherapy and technology development. Before joining AffyImmune Therapeutics, he led development efforts at Antigen Express advancing the clinical development of novel cancer immunotherapies. Prior to that he held positions of increasing responsibility at Millennium Pharmaceuticals aligning novel technology initiatives with genomics-based drug development objectives.



Tasuku Kitada, PhD

President and Head of R&D of Strand Therapeutics

Progamming mRNA for Cancer Immunotherapy

Dr. Tasuku Kitada is President and Head of R&D of Strand Therapeutics. He co-founded Strand and serves on its Board of Directors. Prior to Strand, Dr. Kitada was Senior Biotechnology Analyst at Candriam Investors Group, where he conducted due diligence for the company’s multi-billion-dollar biopharma public equity investment strategy. At Candriam, he focused on cell and gene therapy companies, and also covered numerous oncology companies. Currently, Dr. Kitada continues to serve Candriam Investors Group as an advisor. Prior to Candriam, Dr. Kitada was a researcher at the Synthetic Biology Center at MIT, where he became the first scientist to create synthetic gene circuits using synthetic mRNA. This was the first demonstration of post-transcriptional circuits that can be “wired” to create a variety of networks of increasing complexity, which enabled cell type specific expression as well as small-molecule based control of gene expression from synthetic mRNA. This important research led to publications in Science, Nature Biotechnology, and Nature Chemical Biology. The mRNA synthetic biology platform developed from this research has been exclusively licensed to Strand. Dr. Kitada holds a Ph.D. in Molecular Biology from the University of California, Los Angeles and a B.S. in Biophysics and Biochemistry from the University of Tokyo.



David Lebwohl, PhD

EVP and CMO of Intellia Therapeutics

CRISPR/Cas9 In Vivo Genome Editing for Transthyretin Amyloidosis: First Clinical Results

Dr. David Lebwohl is the Chief Medical Officer at Intellia Therapeutics, a genome editing company. Before Intellia, Dr. Lebwohl was the Chief Medical Officer at Semma Therapeutics Inc., and led drug development teams at Novartis Pharmaceuticals and Bristol Myers Squibb. At Novartis, he was Senior Vice President and Program Head, CAR-T Teams, responsible for the development of the breakthrough

therapy Kymriah® (tisagenlecleucel), approved for leukemia and lymphoma. Under his leadership,

the blockbuster drug Afinitor® (everolimus) was approved for metastatic breast, neuroendocrine, and

kidney cancer as well as the rare genetic disease tuberous sclerosis. Dr. Lebwohl received an AB in

Biochemical Sciences from Harvard College and an MD from Yale University. He completed his

fellowship training at Memorial Sloan Kettering Cancer Center in medical oncology and hematology

and his residency in internal medicine at the Brigham and Women’s Hospital in Boston.


Zoom Meeting


8:45 am - 12:15 pm EST

ID: 87540625701

Passcode: 718858



CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

昆士市聖誕節慶大遊行 好熱鬧

昆士市市長Tom Koch夫婦邀聖誕老人和市民提前慶祝節日來到。(圖片來源:昆士市政府)

    (Boston Orange整理編譯) 1126日晚在興國街亞當斯公園前,就著璀璨燈光辦歌唱遊樂會,1128日再來場聖誕大遊行。昆士市市長Tom Koch率隊策畫的這個歡慶節日週末好熱鬧,街上人頭湧湧,市民好開心。

迪士尼卡通人物穿梭現場,百老匯明星Liz Callaway獻唱,聖誕老人搭直昇機從天而降,昆士市自己的高中軍樂隊演奏,裝扮各有特色的花車列隊走過,吸引許多人26日晚擠到昆士市政府前的亞當斯公園,28日穿得像包成粽子,也要沿街擺出小板凳的欣賞這難得的,已睽違至少一年的假日景象。


參加遊行的軍樂隊中,北昆士高中的樂隊贏得大獎,新貝福(New Bedford)高中第二名,瑪莉完美之心學校(Immaculate Heart of Mary School)贏得第三名。

27號那天從直升機上從天而降,來到選美場(Pageant Field)的聖誕老人,在28日遊行這天,搭乘消防車參加遊行。

圍觀遊行的昆士市民,有許多人每年來看遊行,已連看了30年。一名去年搬到昆士市的居民,為自己今年看到遊行,感到很興奮,直說這可媲美紐奧良的嘉年華會了(Mardi Gras)

昆士市聖誕節委員會主席Barry Welch也說,今年圍觀的人比往年更多。看來人們都很渴望生活恢復正常。他也很高興自己能籌畫推出這第68次的聖誕大遊行。